Results 101 to 110 of about 38,575 (293)

Computationally Driven Structure Optimization, Synthesis, and Biological Evaluation of Imidazole-Based Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) Inhibitors.

Journal of Medicinal Chemistry, 2019
Proprotein convertase subtilisin/kexin 9 (PCSK9) is responsible for the degradation of the hepatic low-density lipoprotein receptor (LDLR), which in turn regulates the circulating low-density lipoprotein cholesterol (LDL-C) level.
C. Lammi, Jacopo Sgrignani, A. Arnoldi, G. Lesma, Claudia Spatti, A. Silvani, G. Grazioso   +6 more
semanticscholar   +1 more source

Cleavage activates Dispatched for Sonic Hedgehog ligand release

eLife, 2018
Hedgehog ligands activate an evolutionarily conserved signaling pathway that provides instructional cues during tissue morphogenesis, and when corrupted, contributes to developmental disorders and cancer.
Daniel P Stewart, Suresh Marada, William J Bodeen, Ashley Truong, Sadie Miki Sakurada, Tanushree Pandit, Shondra M Pruett-Miller, Stacey K Ogden   +7 more
doaj   +1 more source

Clinical studies of monoclonal antibodies against the proprotein convertase subtilisin / kexin type 9

Атеросклероз, 2015
The review presents the current data of scientific literature about different phases of clinical trials of monoclonal antibodies against the proprotein convertase subtilisin/kexin type 9 (PCSK9). The results of completed clinical trials and the review of
K. S. Astrakova, Yu. I. Ragino, E. V. Shakhtshneider, M. I. Voevoda   +3 more
doaj  

Convertases other than furin cleave β‐secretase to its mature form [PDF]

, 2001
An aspartyl protease, Beta‐Site APP cleaving enzyme (BACE), was identified as the β‐secretase responsible for generating the Amyloid β protein that is believed to cause Alzheimer’s disease.
Council, Jenny E., Mallender, William, Onstead, Luisa, Pinnix, Inga, Roseberry, Beverly, Sambamurti, Kumar, Sucic, Joseph   +6 more
core   +1 more source

Development of vaccine for dyslipidemia targeted to a proprotein convertase subtilisin/kexin type 9 (PCSK9) epitope in mice

PLoS ONE, 2018
Proprotein convertase subtilisin/kexin type 9 (PCSK9) regulates expression of low-density lipoprotein (LDL) receptors via receptor internalization and subsequent lysosomal degradation.
R. Kawakami, Yoichi Nozato, H. Nakagami, Yuka Ikeda, M. Shimamura, Shota Yoshida, Jiao Sun, T. Kawano, Y. Takami, T. Noma, H. Rakugi, T. Minamino, R. Morishita   +12 more
semanticscholar   +1 more source

Small molecules as inhibitors of PCSK9: current status and future challenges [PDF]

, 2019
Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays an important role in regulating lipoprotein metabolism by binding to low-density lipoprotein receptors (LDLRs), leading to their degradation.
Luo, Shanshan, Xu, Jinyi, Xu, Shengtao, Zhu, Zheying   +3 more
core   +2 more sources

Inhibition of proprotein convertases-1, -7 and furin by diterpines of Andrographis paniculata and their succinoyl esters [PDF]

, 1999
Ajoy Basak, Sam F. Cooper, Andrée G. Roberge, Upen K. BANIK, Michel Chrètien, Nabil G. Seidah   +5 more
openalex   +2 more sources

The Sirt1 activator SRT3025 provides atheroprotection in Apoe−/− mice by reducing hepatic Pcsk9 secretion and enhancing Ldlr expression [PDF]

, 2017
Aims The deacetylase sirtuin 1 (Sirt1) exerts beneficial effects on lipid metabolism, but its roles in plasma LDL-cholesterol regulation and atherosclerosis are controversial.
Arsiwala, Tasneem, Auwerx, Johan, Ellis, James L., Gomes, Ana P., Hottiger, Michael O., Lohmann, Christine, Lutz, Thomas A., Lüscher, Thomas F., Matter, Christian M., Miranda, Melroy X., Schoonjans, Kristina, Sinclair, David A., Staels, Bart, Stein, Sokrates, Suri, Vipin, Tailleux, Anne, van Tits, Lambertus J., Winnik, Stephan   +17 more
core  

Prevalence and pharmacologic management of familial hypercholesterolemia in an unselected contemporary cohort of patients with stable coronary artery disease [PDF]

, 2018
INTRODUCTION: Familial hypercholesterolemia (FH) is an inherited disorder characterized by elevated plasma levels of low-density lipoprotein cholesterol (LDL-C) associated with premature cardiovascular disease. METHODS: Using the data from the START
A., Gulizia, Arca, M., Bosco, B., Callerame, M., Colivicchi, F., De Luca, L, Di, Lenarda, Gonzini, L., Lettica, G. V., Lucci, D., Temporelli, P. L.   +10 more
core   +1 more source

The AT04A vaccine against proprotein convertase subtilisin/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE*3Leiden.CETP mice

European Heart Journal, 2017
Aims Proprotein convertase subtilisin/kexin type 9 (PCSK9) has emerged as a promising therapeutic target for the treatment of hypercholesterolaemia and atherosclerosis.
C. Landlinger, M. Pouwer, C. Juno, J. V. D. van der Hoorn, E. Pieterman, J. Jukema, G. Staffler, H. Princen, G. Galabova   +8 more
semanticscholar   +1 more source